MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Biogen Inc

Suletud

SektorTervishoid

131.76 -3.65

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

131.24

Max

136.89

Põhinäitajad

By Trading Economics

Sissetulek

-122M

267M

Müük

-15M

2.5B

P/E

Sektori keskmine

12.677

73.239

Aktsiakasum

3.44

Kasumimarginaal

10.865

Töötajad

7,605

EBITDA

-158M

536M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+45.75% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

23. apr 2025

Turustatistika

By TradingEconomics

Turukapital

-509M

21B

Eelmine avamishind

135.41

Eelmine sulgemishind

131.76

Uudiste sentiment

By Acuity

61%

39%

320 / 386 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

Biogen Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. sept 2024, 11:00 UTC

Peamised uudised

Pandemic Darling Moderna Needs a Reality Check -- Heard on the Street -- WSJ

29. mai 2024, 15:56 UTC

Tulu
Omandamised, ülevõtmised, äriostud

The Moderna Selloff Gains Steam. An Analyst Has a Few Theories Why. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Biogen Inc Prognoos

Hinnasiht

By TipRanks

45.75% tõus

12 kuu keskmine prognoos

Keskmine 192.43 USD  45.75%

Kõrge 265 USD

Madal 135 USD

Põhineb 25 Wall Streeti analüütiku instrumendi Biogen Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

25 ratings

13

Osta

12

Hoia

0

Müü

Tehniline skoor

By Trading Central

N/A / 141.43Toetus ja vastupanu

Lühikene perspektiiv

Strong Bearish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

320 / 386 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.